Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 16 2021 - 8:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of December 2021
Commission
File Number: 001-36582
Altamira
Therapeutics Ltd.
(formerly
Auris Medical Holding Ltd.)
(Exact
name of registrant as specified in its charter)
Clarendon
House, 2 Church Street
Hamilton
HM 11, Bermuda
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes
☐ No ☒
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes
☐ No ☒
On
December 16, 2021, Altamira Therapeutics Ltd. (the “Company”) announced the appointment of Marcel Gremaud, CPA, as
Chief Financial Officer, effective December 20, 2021. Mr. Gremaud will succeed Elmar Schärli, who is resigning from his position
as Chief Financial Officer of the Company. Mr. Schärli will continue to work for the Company in the fields of treasury management
and tax. Mr. Gremaud has been working for the Company since 2013 in the fields of IFRS and consolidation. He acquired more than 30 years’
experience in controlling and accounting in international pharma companies and start-ups. In 2001 he founded Gremaud GmbH, an audit and
accounting company supporting companies in financial consolidation and accounting in accordance with IFRS, US GAAP or Swiss GAAP FER.
INCORPORATION
BY REFERENCE
This
Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-228121, 333-249347
and 333-261127) and
Form S-8 (Registration Number 333-232735
and 333-252141) of
Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) and to be a part thereof from the date on which this report is
filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Altamira Therapeutics Ltd.
|
|
|
|
By:
|
/s/ Thomas Meyer
|
|
|
Name:
|
Thomas Meyer
|
|
|
Title:
|
Chief Executive Officer
|
Date:
December 16, 2021
2
Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Apr 2024 to May 2024
Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From May 2023 to May 2024